Oxford Biomedica PLC Directors Dealings / Market Share Purchases (9538J)

TIDMOXB

RNS Number : 9538J

Oxford Biomedica PLC

29 April 2022

Directors Dealings / Market Share Purchases

Oxford, UK - 29 April 2022: Oxford Biomedica plc ("Oxford Biomedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, today announces that Catherine Moukheibir, a Non-Executive Director of the Company, has purchased shares in the Company.

As stated in the Oxford Biomedica 2021 Remuneration Policy which was approved at the 2021 Annual General Meeting, an additional fee of up to GBP50,000 per annum may be paid to any Non-Executive Director recruited from or based outside of the UK to reflect market levels of remuneration based for Non-Executive Directors not based in the UK, subject to their agreement that the after tax amount of this additional fee will be used to acquire Oxford Biomedica shares at market value, which must be retained for at least 12 months from acquisition.

Catherine Moukheibir has purchased 2,467 ordinary shares of 50p each ("Ordinary Shares") in the Company on 29 April 2022 on the London Stock Exchange at a price of 570.9p under the terms of a market purchase agreement. Following this purchase Catherine Moukheibir holds 2,467 Ordinary Shares representing 0.002% of the Company.

The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the number of Ordinary Shares purchased.

 
 1.   Details of the person discharging material responsibilities/person 
       closely associated 
 a.   Name                                         Catherine Moukheibir 
 2.   Reason for the notification 
 a.   Position/status                              Non-Executive Director 
 b.   Initial notification                         Initial notification 
       /amendment 
3.    Details of the issuer, emission allowance, market 
       participant, auction platform, auctioneer or auction 
       monitor 
 a.   Name                                         Oxford Biomedica plc 
 b.   Legal Entity Identifier                      213800S1GVQNXQ15K851 
4.    Details of the transaction(s); section to be repeated 
       for (i) each type of instrument; (ii) each type of 
       transaction; (iii) each date; and (iv) each place 
       where transactions have been conducted 
 a.   Description of                               Oxford Biomedica plc Ordinary Shares 
       the financial                                of 50p each 
       instrument, type                             GB00BDFBVT43 
       of instrument 
       identification 
       code 
b.    Nature of the                                Purchase of ordinary shares 
       transaction 
c.    Currency                                     GBP - British Pound 
d.    Price(s) and volume(s)                             Price(s)               Volume(s) 
                                 GBP5.71                                          2,467 
 
e.          Aggregated information                 2,467 
              *    Aggregated volume                GBP5.70903 
                                                    GBP14,084.18 
 
              *    Price 
 
 
              *    Aggregated total 
f.    Date of the transaction                      2022-04-29 
g.    Place of the transaction                     London Stock Exchange, Main Market (XLON) 
 

-Ends-

 
 For further information, please contact: 
  Oxford Biomedica plc:                      Tel: [phone] 
   Natalie Walter, Company Secretary 
 

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is an innovative leading viral vector specialist focused on delivering life changing therapies to patients.

Oxford Biomedica plc and its subsidiaries (the Group) work across key viral vector delivery systems including those based on lentivirus, adeno-associated virus (AAV) and adenovirus, providing innovative solutions to cell and gene therapy biotechnology and biopharma companies for their process development, analytical development and manufacturing needs. Oxford Biomedica has built a sector leading lentiviral vector delivery system, LentiVector(R) platform, which the Group leverages to develop product candidates in-house, before seeking partners to take the products into clinical trials.

Oxford Biomedica is based across several locations and headquartered in Oxfordshire, UK. In early 2022, the Group established Oxford Biomedica Solutions, a new US based subsidiary AAV manufacturing and innovation business, based near Boston, US.

Oxford Biomedica employs more than 940 people. Further information is available at www.oxb.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHFLFVRSAIAFIF

(END) Dow Jones Newswires

April 29, 2022 12:42 ET (16:42 GMT)